Find your next paid study

Memorial Sloan Kettering Cancer CenterNCT07323732

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors

This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

UNC Lineberger Comprehensive Cancer CenterNCT07630168

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-IIIEsophagogastric Cancer Stage I-III+2 more

The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear a…

University of Wisconsin, MadisonNCT07132918

Non Small Cell Lung CancerCardiotoxicityLocally Advanced Non-Small Cell Lung Cancer+1 more

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer

Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced No…

Indiana UniversityNCT07761910

Phase 1

A Phase 1/2, Multicenter, Multi-cohort, Open-label Study of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen With IOV-5001 in Participants With Previously Treated Advanced Solid Tumors

A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previ…

Advanced Solid TumorsNon-Small Cell Lung CancerTriple Negative Breast Cancer (TNBC)+4 more

Iovance Biotherapeutics, Inc.NCT07743723

~$10 – $8,750

Phase 3

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum…

Non-small Cell Lung Cancer

Daiichi SankyoNCT06899126

~$10 – $7,500

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-s…

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more

Guardant Health, Inc.NCT05059444

~$10 – $1,050

Phase 1

A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 …

Ovarian CancerNon-small Cell Lung Cancer

~$10 – $8,750

Tubulis GmbHNCT06303505

Non-Small Cell Lung Cancer

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The…

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with…

Metastatic Non-small Cell Lung Cancer

Memorial Sloan Kettering Cancer CenterNCT04410796

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response …

Non-small Cell Lung CancerColorectal CancerBreast Cancer

Guardant Health, Inc.NCT05935384

~$10 – $1,050

Phase 1

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-can…

Breast CancerBiliary Tract CarcinomaOvarian Cancer+2 more